Course Description
The Psychiatric Pharmacotherapy Review Book is designed for use by individuals preparing to sit for the Board Certified Psychiatric Pharmacist (BCPP) examination. AAPP surveys show that at least 90% of successful BCPP candidates purchase the Review Book as their primary study tool. One hundred percent of survey respondents indicate that the Review Book was their primary study resource and a key tool to their certification success.
The Book Contains:
- Comprehensive outlines, written as individual chapters, of the most common psychiatric and neurologic conditions tested for in the BCPP exam.
- Consistently formatted chapters that include objectives, thorough content, comprehensive reference listings, and self-assessment questions with answer justifications.
- An e-book version of the book hosted VitalSource Bookshelf, a leading e-textbook solution. This e-book version allows you to take electronic notes as well as download the book to your desktop or mobile device for off line access. The pricing above reflects the cost for the digital version of the book. There is an additional fee for shipping a hard copy of the book and this option can be selected upon check-out.
To maintain its strict, independent standards for certification, BPS does NOT develop, endorse, or support review information, preparatory courses, or study guides.
Learning Objectives
Topic |
---|
Anxiety and Anxiety-Related Disorders(2 ACPE hours) ACPE #0284-0000-24-002-H01-P (Knowledge)
|
Biostatistics and Research Design in Psychiatry(2.5 ACPE hours) ACPE #0284-0000-24-003-H04-P (Knowledge)
|
Bipolar Disorder(1.5 ACPE hours) ACPE #0284-0000-24-004-H01-P (Knowledge)
|
Depression(1.5 ACPE hours) ACPE #0284-0000-24-005-H01-P (Knowledge)
|
Introduction to Psychiatric Pharmacy(0.5 ACPE hours) ACPE #0284-0000-24-001-H04-P (Knowledge)
|
Neurocognitive Disorders(1 ACPE hour) ACPE #0284-0000-24-006-H01-P (Knowledge)
|
Neurodevelopmental, Disruptive, Impulse-Control and Conduct Disorders(1 ACPE hour) ACPE #0284-0000-24-007-H01-P (Knowledge)
|
Neurologic Disorders(2.5 ACPE hours) ACPE #0284-0000-24-008-H01-P (Knowledge)
|
Personality Disorders and Eating Disorders(0.5 ACPE hours) ACPE #0284-0000-24-009-H01-P (Knowledge)
|
Regulatory Issues in Pharmacy Practice(2 ACPE hours) ACPE #0284-0000-24-010-H04-P (Knowledge)
|
Schizophrenia Spectrum and Other Psychotic Disorders(2 ACPE hours) ACPE #0284-0000-24-011-H01-P (Knowledge)
|
Sleep-Wake Disorders(1.5 ACPE hours) ACPE #0284-0000-24-012-H01-P (Knowledge)
|
Substance-Related Disorders(1.5 ACPE hours) ACPE #0284-0000-24-013-H01-P (Knowledge)
|
Target Audience
The Psychiatric Pharmacotherapy Review Book is designed for three primary audiences:
- It serves as a preparatory book for pharmacists preparing to sit for the BCPP examination.
- It offers a review of current evidence-based pharmacotherapy for psychiatric and neurologic conditions for BCPP certified pharmacists seeking BCPP recertification credit (purchase here).
- It serves as an educational tool for other healthcare providers on current evidence-based pharmacotherapy for psychiatric and neurologic conditions.
NOTE: The Psychiatric Pharmacotherapy Review Book is a two-year product released at the start of even years (2024, 2026...).
Faculty
View biographical information
Western New England University
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Antipsychotics for Behavioral and Psychiatric Symptoms of Dementia
Continuing Education Credit and Disclosures
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
2024-2025 Editorial Board
All relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.
In accordance with the Food and Drug Administration (FDA), it is disclosed that there is the potential for discussions concerning off-label uses of a commercial product/devices during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in this activity. Significant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.